MedTrace Logo

How Dose Coenzyme Q10 Supplementation During Infertility Treatment Effects Pregnancy Outcome

NCT00878124 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2010-01-12

No results posted yet for this study

Summary

As women age the ovarian response and pregnancy rate are reduced while the rate of chromosomal abnormalities in the embryos is increased. Oocyte maturation, accurate chromosomal segregation as well as early embryo development and implantation are dependent on the supply of large amounts of energy, which unlike other cells can only arise from the mitochondria. With age the mitochondria becomes less efficient due to damage to its unique DNA, resulting in decreased energy production. The proposed study will examine the effect of the combination of a dietary supplement, Co enzyme Q10 on pregnancy rate and response of the ovaries to a medication that stimulates follicle growth. The investigators hypothesize that the improved energetic state of the oocyte would result in a more accurate chromosomal separation, increased embryo quality and pregnancy rate.

Conditions

  • Poor Ovarian Response

Interventions

DIETARY_SUPPLEMENT

Coenzyme Q10 co treatment

CoenzymeQ10 300mg twice a day continuously. Ceased when patient conceives or at the end of the study.

OTHER

Placebo Caps

3 caps twice a day continuously until pregnant or at the end of the study.

Sponsors & Collaborators

  • Toronto Centre for Advanced Reproductive Technology

    collaborator OTHER

  • Ferring Pharmaceuticals

    collaborator INDUSTRY

  • University of Toronto

    lead OTHER

Principal Investigators

  • Robert F Casper, Prof · University of Toronto

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
38 Years
Max Age
43 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00878124 on ClinicalTrials.gov